That this House expresses deep concern over the decision by Pfizer to award the contract for sole supplying of its pharmaceutical products to one wholesaler Unichem; is alarmed that this has created a de facto monopoly for Unichem in that pharmacies have no choice about who they deal with if they want to purchase Pfizer products; is concerned that whereas choice and competition have kept prices down this action will lead to a worse deal for local pharmacists, the NHS and ultimately the general public; is deeply alarmed that if Unichem had a crisis in its distribution then other wholesalers would be unable to fill the gap left and thus people might not get the pharmaceutical products they absolutely rely on; and calls on the Office of Fair Trading and the Department of Health to investigate this issue with a focus on, respectively, the effect of this decision on unfair business practices and public health.

That this House expresses deep concern over the decision by Pfizer to award the contract for sole supplying of its pharmaceutical products to one wholesaler Unichem; is alarmed that this has created a de facto monopoly for Unichem in that pharmacies have no choice about who they deal with if...